Allergan Reports Third Quarter 2013 Operating Results

By

IRVINE, Calif.—For the quarter ended Sept. 30, 2013, Allergan (NYSE: AGN) reported $1,528.4 million in total product net sales, a 12.9 percent increase compared to total product net sales in the third quarter of 2012. On a constant currency basis, total product net sales increased 14.0 percent compared to total product net sales in the third quarter of 2012.

Total specialty pharmaceuticals net sales increased 12.8 percent, or 13.9 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the third quarter of 2012. Eyecare pharmaceuticals net sales rose to $717.1 million, up 8.1 percent from year ago, or 9 percent on a constant currency basis.

Total medical devices net sales increased 13.4 percent, or 14.6 percent on a constant currency basis, compared to total medical devices net sales in the third quarter of 2012.

“We are pleased with our continued broad based double digit sales and earnings growth performance during the third quarter driven by both our pharmaceutical and medical device businesses,” said David E.I. Pyott, Allergan’s chairman of the board and CEO.